EWTX News and Press, Edgewise Therapeutics Inc. From 03/14/23

– Podium presentation on March 22, 2023 – – Company to host an Industry Forum to discuss its new approach to protecting dystrophic muscle featuring a key opinion leader – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceu...

– President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavaila...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the Cowen 43rd Annual Health Car...

– Presentation highlights EDG-7500, an investigational first-in-class oral, selective, sarcomere modulator for hypertrophic cardiomyopathy (HCM) on March 5, 2023 – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developi...

Reata Pharmaceuticals ( NASDAQ: RETA ) lost ~32% on Monday to reach the lowest level in over four months as a key FDA official leaves the agency while the company awaits the U.S. approval for its Friedreich's ataxia ((F.A.)) therapy, omaveloxolone. Earlier in the day, multiple new...

Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q4 GAAP EPS of -$0.31 beats by $0.05 . Cash, cash equivalents and marketable securities were $352 million as of December 31, 2022. For further details see: Edgewise Therapeutics GAAP EPS of -$0.31 beats by $0.05

– Advancing Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON ) and Duchenne muscular dystrophy (DMD, LYNX); Initiated Phase 2 exercise challenge trial of EDG-5506 in Limb girdle muscular dystrophy 2i (LGMD2I), BMD and McArdle’s Disease (DUNE) ...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the virtual SVB Securities Globa...

Summary Edgewise Therapeutics, Inc. develops small molecules for musculoskeletal diseases. Early data in BMD has been very strong. The company is set for cash. Edgewise Therapeutics, Inc. (EWTX) is a developer of small molecule therapies for musculoskeletal diseases. The p...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41 st Annual...